[go: up one dir, main page]

WO2007061554A3 - Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries - Google Patents

Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries Download PDF

Info

Publication number
WO2007061554A3
WO2007061554A3 PCT/US2006/041302 US2006041302W WO2007061554A3 WO 2007061554 A3 WO2007061554 A3 WO 2007061554A3 US 2006041302 W US2006041302 W US 2006041302W WO 2007061554 A3 WO2007061554 A3 WO 2007061554A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treatment
nerve tissue
compositions
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/041302
Other languages
French (fr)
Other versions
WO2007061554A2 (en
Inventor
Ryi Shi
Richard B Borgens
Daniel T Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of WO2007061554A2 publication Critical patent/WO2007061554A2/en
Publication of WO2007061554A3 publication Critical patent/WO2007061554A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides novel pyridines, pharmaceutical compositions comprising such pyridines, and the use of such compositions in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord, in one embodiment, the compounds, compositions, and methods of the instant invention treat a mammalian nerve tissue injury by restoring action potential or nerve impulse conduction through a nerve tissue lesion. Significantly, in vivo application of compounds of the instant invention established, on the basis of SSEP testing, that the compounds provide longer lasting effects at lower concentrations than comparable treatment with the known agent 4-aminopyridine (4 AP).
PCT/US2006/041302 2005-10-21 2006-10-23 Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries Ceased WO2007061554A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72896005P 2005-10-21 2005-10-21
US60/728,960 2005-10-21

Publications (2)

Publication Number Publication Date
WO2007061554A2 WO2007061554A2 (en) 2007-05-31
WO2007061554A3 true WO2007061554A3 (en) 2007-10-11

Family

ID=38067700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041302 Ceased WO2007061554A2 (en) 2005-10-21 2006-10-23 Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries

Country Status (1)

Country Link
WO (1) WO2007061554A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125503C2 (en) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Substituted tricyclic compounds as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
UA121669C2 (en) 2015-02-20 2020-07-10 Інсайт Корпорейшн BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
CN112566912A (en) 2018-05-04 2021-03-26 因赛特公司 Salts of FGFR inhibitors
SI3788047T1 (en) 2018-05-04 2024-11-29 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20240024216A1 (en) * 2021-01-06 2024-01-25 The Penn State Research Foundation Methods and materials for treating hair loss
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US20040171587A1 (en) * 2002-12-06 2004-09-02 Borgens Richard B. Pyridines for treating injured mammalian nerve tissue

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US20040171587A1 (en) * 2002-12-06 2004-09-02 Borgens Richard B. Pyridines for treating injured mammalian nerve tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMITH D.T. ET AL.: "Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 1 August 2005 (2005-08-01), pages 908 - 917 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
WO2007061554A2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2007061554A3 (en) Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
WO2004052291A3 (en) Pyridines for treating injured mammalian nerve tissue
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
ATE528002T1 (en) PYRIDONE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENESIS-MEDIATED DISEASES
WO2007128817A3 (en) Insulin derivative
WO2008054544A3 (en) Method for delivery across the blood brain barrier
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TNSN07376A1 (en) Npy antagonists, preparation and use
WO2007098089A3 (en) Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
WO2005042498A3 (en) 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
BR0012175A (en) Igiur5 receptor antagonists, selective for the treatment of migraine
AU9543601A (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
BRPI0409796A (en) use of dipyridamole or mopidamole for treatment and prevention of thromboembolic disorders and disorders caused by excessive thrombin formation and / or elevated expression of thrombin receptors
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2006086693A3 (en) Medical devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06826478

Country of ref document: EP

Kind code of ref document: A2